• Alectinib is a second generation ALK antagonist that is buil

  2023-11-09

  

  Alectinib is a second generation ALK antagonist that is built upon a 9-ethyl-6, 6-dimethyl-11-oxo benzo[b]carbazole scaffold (Fig. 5C) [58]. This drug is effective against the ALK L1196M gatekeeper mutation along with C1156Y and F1174L mutations [7]. The 11-oxo group of the drug forms a flt3 with t

• To guide our attempts at achieving AKT potency and selectivi

  2023-11-09

  

  To guide our attempts at achieving AKT potency and selectivity against p70S6K and other kinases from (p70 S6K IC: 0.004 μM) and , we took advantage of exploiting the subtle sequence differences in the active sites of the AGC family kinases, we utilized the information around crystal structure of AK

• The assay performance was estimated

  2023-11-09

  

  The assay performance was estimated using Z′-factors (plotted in Fig. 2A) according to Zhang et al. calculated for each plate comparing positive (in the absence of an inhibitor) and negative controls (in the presence of an AdK inhibitor). The mean Z′-factor±SD was determined to be 0.7±0.1, indicativ

• j 14 In order to investigate their effects in

  2023-11-09

  

  In order to investigate their effects in vitro, therefore, we first used TE671 cells, which have provided a useful source of human AChR for in vitro and radioimmunoassay studies. We found no marked effect of either MuSK-MG or SNMG sera on AChR numbers or on AChR subunit expression. This appears to c

• br Disclosure statement br Acknowledgements The

  2023-11-09

  

  Disclosure statement Acknowledgements The work was supported by the National Science Foundation of China (Nos. 81273526, 81473268) and Natural Science Foundation of Colleges and Universities (Nos. KJ2017A197). What is already known What this article adds Introduction Sevoflurane is o

• Although CP has been an important research subject

  2023-11-09

  

  Although CP has been an important research subject in the field of antigen processing and presentation, the mechanisms of presentation of intracellular Cy3 maleimide (non-sulfonated) by MHC II received considerably less attention. Interestingly, pioneering work by the Münz laboratory has pointed to

• A positive correlation between nasopharyngeal CCL and CCL co

  2023-11-09

  

  A positive correlation between nasopharyngeal CCL3 and CCL5 [16] concentrations and illness severity was shown in evaluating patients with RSV bronchiolitis [17]. CCL5 and CCL3 are important for monocyte and lymphocyte recruitment to the lung during RSV infection [7], [16], [18]. Despite the signifi

• br Author contributions br Conflicts of interest The authors

  2023-11-09

  

  Author contributions Conflicts of interest The authors declare no competing financial interests. Acknowledgement This work was supported by grants from the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich/Transregio 166–Project C1 and grant CA 1014/1-1 to D.C.) and the IZKF Würzbur

• ASK belongs to the family of

  2023-11-09

  

  ASK1 belongs to the family of MAPKKK. ASK1-mediated apoptosis is involved in the pathogenesis of several diseases such as I/R injury, infectious diseases and neurodegenerative disorders [33], [34], [35]. ASK1 can be activated through different mechanisms. One mechanism is that oxidative stress direc

• Weak and transient interactions of HMGB proteins in such

  2023-11-08

  

  Weak and transient interactions of HMGB proteins in such hit-and-run mechanisms are understandable given that “fluorescence loss in photobleaching” (FLIP) experiments employing GFP-labeled HMGBs have shown that in living cells they are the most mobile of all nuclear proteins [144]. The entire pool o

• Furthermore a study in Drosophila has reported

  2023-11-08

  

  Furthermore, a study in Drosophila has reported that Dpatj can interact directly with Dmpar6 providing another potential mechanism linking the Crb to the Par complex [163]. In contrast, Wang et al. in 2004 [63] have shown that at least in MDCK epithelial cells, PAR6 binding to PALS1 interferes with

• br Declarations Funding None for

  2023-11-08

  

  Declarations Funding: None for the paper in question. Competing interests: Florent Morio has received speaker's fees from Gilead, Basilea, and MSD and travel grants from Gilead, MSD, Pfizer, Basilea, and Astellas. Ethical approval: Not relevant for the paper in question. Introduction Lactic

• Most clinically approved antiangiogenic drugs are

  2023-11-08

  

  Most clinically approved antiangiogenic drugs are aimed at blocking the action of vascular endothelial growth factor, or VEGF, which is accepted to be the most important tumor-derived angiogenic factor, stimulating proliferation and migration of endothelial cells, as well as branching of vessels (Fe

• 5-(N,N-dimethyl)-Amiloride hydrochloride In our previous wor

  2023-11-08

  

  In our previous work, diffuse deposition patterns of neocortical Aβ and a hierarchical upward spreading pattern of tau were determined with in vivo 18F-florbetaben and 18F-flortaucipir positron emission tomography (PET) studies, based on the regional frequency of involvement by tau and Aβ (Cho et al

• br Conflict of interest statement br

  2023-11-08

  

  Conflict of interest statement Introduction Tanshinone IIA (Tan IIA) is a major active component of Salvia miltiorrhiza (S. miltiorrhiza), a well-known Chinese traditional medicine that is used for the treatment of cardiovascular and cerebrovascular diseases [1]. Tan IIA exhibits diverse pharm

13604 records 194/907 page Previous Next First page 上5页 191192193194195 下5页 Last page